Table 4.

The 3-month survival rate amongst older patients with digestive system cancer, by period and year.

	Pre-lockdown perioda				Lockdown periodb				Post-lockdown periodc
	2018	2019	2020	pd	2018	2019	2020	pd	2018	2019	2020	pd
All patients	81.1	81.9	81.2	0.89	78.9	81.1	81.7	0.57	82.0	79.2	82.8	0.06
Age group
65–69	90.3	86.6	86.5	0.37	81.0	87.6	87.1	0.23	87.6	84.5	88.8	0.38
70–79	82.7	85.2	86.3	0.46	87.9	86.2	85.2	0.69	85.3	83.8	85.1	0.78
≥80	70.5	72.6	68.5	0.50	62.2	64.0	69.8	0.61	71.0	67.7	74.8	0.07
Sex
Male	81.3	83.4	84.8	0.40	79.8	82.6	83.9	0.48	83.1	81.4	82.1	0.76
Female	80.9	79.8	74.5	0.12	77.4	78.4	78.4	0.96	80.3	75.8	83.9	0.011
Primary tumour site
Colon + rectum	87.4	85.7	84.6	0.58	80.2	86.5	85.8	0.18	84.9	83.7	87.2	0.29
Oesophagus + gastric	79.1	80.7	85.5	0.65	75.4	80.5	75.0	0.81	82.7	81.0	74.7	0.24
Pancreas + bile duct	73.1	74.8	74.7	0.88	77.3	71.8	80.3	0.35	75.2	73.4	80.7	0.10
Hepatocellular carcinoma	77.9	85.1	83.1	0.33	77.2	85.5	78.7	0.31	84.3	76.5	85.1	0.06
Small intestine	95.2	95.0	81.0	0.25	100.0	85.4	83.3	0.38	95.8	89.4	76.7	0.08
Anus	86.7	83.9	87.1	0.96	90.5	74.1	92.3	0.36	94.1	72.2	68.1	0.13
Tumour stage
Non-metastatic	87.1	87.5	86.7	0.86	83.6	87.2	85.3	0.30	88.3	87.0	88.1	0.57
Metastatic	55.5	58.8	56.3	0.80	59.2	57.3	63.5	0.83	58.2	47.8	61.0	0.021
Charlson Comorbidity Index
≤3	91.3	89.2	88.6	0.30	85.3	88.5	88.5	0.49	90.7	89.2	89.1	0.58
>3	70.6	73.5	72.9	0.64	72.5	72.4	74.9	0.92	72.9	69.3	76.2	0.048

^aPatients newly treated for a digestive system cancer between January 1st, 2020, and March 16th, 2020, and followed up for 3-month survival.

^bPatients newly treated for a digestive system cancer between March 16th, 2020 and May 10th, 2020, and followed up for 3-month survival.

^cPatients newly treated for a digestive system cancer between May 11th, 2020, and August 30th, 2020, and followed up for 3-month survival.

^dlog-rank test.